Core Insights - IQVIA Holdings reported quarterly earnings of $3.12 per share, exceeding the Zacks Consensus Estimate of $3.10 per share, and up from $2.84 per share a year ago, indicating a 9.86% year-over-year increase [1] - The company achieved revenues of $3.96 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.89% and showing a year-over-year increase from $3.87 billion [2] - IQVIA has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating strong operational performance [2] Earnings Outlook - The sustainability of IQVIA's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - Current consensus EPS estimate for the upcoming quarter is $2.59 on revenues of $3.85 billion, while for the current fiscal year, the estimate is $11.80 on revenues of $16.02 billion [7] Industry Context - The Medical - Instruments industry, to which IQVIA belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Fourth-quarter revenue was $3,958 million, a 2.3% increase year-over-year, with full-year revenue of $15,405 million, up 2.8%[4] - Technology & Analytics Solutions (TAS) revenue for Q4 was $1,658 million, growing 8.3% year-over-year, while full-year TAS revenue reached $6,160 million, up 5.1%[4][7] - Research & Development Solutions (R&DS) revenue for Q4 was $2,123 million, a decrease of 1.3% year-over-year, with full-year R&DS revenue at $8,527 million, up 1.6%[4][7] - GAAP Net Income for Q4 was $437 million, down 6.8% year-over-year, while full-year GAAP Net Income was $1,373 million, up 1.1%[6][8] - Adjusted EBITDA for Q4 was $996 million, a 3.1% increase year-over-year, with full-year Adjusted EBITDA of $3,684 million, up 3.2%[6][8] - Revenues for Q4 2024 reached $3,958 million, a 2.3% increase from $3,868 million in Q4 2023; total revenues for 2024 were $15,405 million, up 2.8% from $14,984 million in 2023[22] - Net income for Q4 2024 was $437 million, compared to $469 million in Q4 2023; total net income for 2024 was $1,373 million, slightly up from $1,358 million in 2023[22] - Adjusted EBITDA for Q4 2024 was $996 million, a 3.1% increase from $966 million in Q4 2023; total adjusted EBITDA for 2024 was $3,684 million, up from $3,569 million in 2023[29] Cash Flow and Assets - Operating Cash Flow for 2024 was $2,716 million, up 26% year-over-year, and Free Cash Flow was $2,114 million, up 41% year-over-year[9] - Free cash flow for Q4 2024 was $721 million, with total free cash flow for 2024 amounting to $2,114 million[34] - Cash and cash equivalents increased to $1,702 million as of December 31, 2024, compared to $1,376 million at the end of 2023[24] - Total assets grew to $26,899 million in 2024, up from $26,681 million in 2023[24] - Total liabilities increased to $20,832 million in 2024, compared to $20,569 million in 2023[24] Share Repurchase and Guidance - The company repurchased $1.35 billion of its shares in 2024, with an additional $2 billion share repurchase authorization announced in February 2025[10] - The 2025 revenue guidance is set at $15,725 million to $16,125 million, with Adjusted EBITDA expected between $3,765 million and $3,885 million[11] - The company anticipates revenue growth at constant currency ex-COVID of 4% to 7% for 2025, with Adjusted Diluted Earnings per Share growth of 5% to 9%[11] Debt and Leverage - As of December 31, 2024, gross debt is reported at $13,983 million[35] - Net debt stands at $12,281 million as of December 31, 2024[35] - The gross leverage ratio is calculated at 3.80x[35] - The net leverage ratio is reported at 3.33x[35] Other Financial Metrics - R&DS contracted backlog as of December 31, 2024, was $31.1 billion, growing 4.4% year-over-year, with an expected revenue conversion of approximately $7.9 billion in the next twelve months[5] - The company reported a restructuring cost of $67 million for the year 2024, down from $84 million in 2023[22] - The weighted average diluted shares outstanding decreased to 180.8 million in Q4 2024 from 184.3 million in Q4 2023[22] - The company repurchased $1,350 million of common stock in 2024, compared to $992 million in 2023[26]

Core Viewpoint - IQVIA Holdings Inc. is set to release its fourth-quarter 2024 results on February 6, with expectations of revenue growth and improved earnings per share compared to the previous year [1][5]. Revenue Expectations - The Zacks Consensus Estimate for IQVIA's revenues is $3.9 billion, reflecting a 1.4% increase from the same quarter last year, driven by improved segment performance [3]. - Revenue from the Research and Development Solutions (RD&S) segment is anticipated to be $2.2 billion, indicating a slight rise from the previous year [4]. - The Technology and Analytics Solutions (TAS) segment is expected to generate $1.6 billion, representing a 3.5% year-over-year increase, attributed to the new AI assistant tool [4]. - Contract sales and Medical solutions revenues are estimated at $187 million, suggesting marginal growth from the prior year [5]. Earnings Expectations - The consensus estimate for earnings per share is $3.1, indicating a 9.5% growth year-over-year, supported by higher revenues and effective cost management [5]. - The adjusted EBITDA for the fourth quarter is projected to be $1 billion, reflecting a 4.4% increase compared to the previous year [5]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for IQVIA, with an Earnings ESP of 0.00% and a Zacks Rank of 3 (Hold) [6].

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

The upcoming report from IQVIA Holdings (IQV) is expected to reveal quarterly earnings of $3.11 per share, indicating an increase of 9.5% compared to the year-ago period. Analysts forecast revenues of $3.92 billion, representing an increase of 1.4% year over year.The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior t ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...

Core Insights - IQVIA Holdings has consistently beaten earnings estimates, particularly in the last two quarters, with an average surprise of 1.70% [1][3] - For the most recent quarter, IQVIA reported earnings of $2.84 per share, exceeding the expected $2.81, resulting in a surprise of 1.07% [2] - The previous quarter also saw a positive surprise, with actual earnings of $2.64 per share against an estimate of $2.58, marking a surprise of 2.33% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for IQVIA, with a positive Earnings ESP of +0.16%, indicating bullish sentiment among analysts [3][6] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high probability of another earnings beat, with historical data showing that nearly 70% of stocks with this combination exceed consensus estimates [4][6] Importance of Earnings ESP - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions which may be more accurate [5] - A negative Earnings ESP does not necessarily indicate an earnings miss but can reduce the predictive power of the metric [6] - It is crucial for investors to check a company's Earnings ESP prior to quarterly releases to enhance the likelihood of successful investment decisions [7]

IQVIA Holdings Inc. (IQV) is benefiting from its ability to standardize, organize and integrate data through analytics and global technology, which boosts its client base. Shareholder-friendly policy is another green flag for investors. Meanwhile, competitive pressure is troublesome and low liquidity poses a threat to the company’s ability to pay off short-term debt.IQV reported impressive third-quarter 2024 results. Adjusted earnings were $2.8 per share, outpacing the Zacks Consensus Estimate by 1.1% and r ...

Company Overview - IQVIA Holdings (IQV) shares increased by 3% to close at $197.27, following a notable trading volume, contrasting with a 3.1% loss over the past four weeks [1] - The rise in stock price is attributed to improvements in the company's short-cycle businesses, driven by clients launching drugs and executing critical commercial programs [1] Earnings Expectations - IQVIA is expected to report quarterly earnings of $3.11 per share, reflecting a year-over-year increase of 9.5% [2] - Revenue projections stand at $3.92 billion, which is a 1.4% increase compared to the same quarter last year [2] Stock Performance Insights - The consensus EPS estimate for IQVIA has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Comparison - IQVIA is part of the Zacks Medical - Instruments industry, which includes Thermo Fisher Scientific (TMO) [3] - TMO's consensus EPS estimate for its upcoming report has increased by 0.1% to $5.92, representing a 4.4% change from the previous year [4] - TMO also holds a Zacks Rank of 3 (Hold) [4]

Join Compounding Healthcare where we employ data analytics in combination with technical analysis and clinical data breakdown in order to manage a position in numerous potential multi-bagger investments that can grow into a comprehensive healthcare portfolio.It has been roughly 10 months from my previous article on IQVIA Holdings (NYSE: IQV ), where I discussed the company's Q4 2023 marks, which beat the Street's expectations thanks to record revenues and EPS growth. At that time, IQVIA publicizedHe is the ...